Half Year Results Presentation
Filed with ASX · · 16 pages · English
Summary by 6ix AI
The report indicates a substantial increase in revenue compared to the previous year, alongside a positive profit after tax and operating cash flow. The company is expanding its global market presence and has made progress in clinical trial execution and technology development. Looking ahead, Resonance maintains its guidance for revenue and EBITDA for the full year, reflecting confidence in its growth strategy.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
In the deck
Story so far
Earlier from Resonance Health
- Half Year Results
- Half Year Report & Accounts
- Quarterly Activities/Appendix 4C Cash Flow Report
- AGM Presentation
- Investor Strategy Day Presentation
Later from Resonance Health
- Receipt of R&D Tax Incentive Refund
- Profit Guidance Upgrade
- Liver Fibrosis Device Progress & FY26 Portfolio Webinar
- Cessation of Quarterly Reporting
- FY26 Full Year Results Webinar
Follow Resonance Health into a list and get an email when it puts out news.
Follow Resonance Health